Decision to award sole supply of metoprolol succinate in New Zealand

6 June 2017

New Zealand’s Pharmaceutical Management Agency PHARMAC today announced the approval of an agreement with the local subsidiary of AstraZeneca (LSE: AZN) for the supply of metoprolol succinate long-acting tablets, sold under the Betaloc and Toprol XL trade names.

“PHARMAC understands the importance of metoprolol succinate for so many New Zealanders,” says PHARMAC director of operations, Sarah Fitt, adding: “While patients have been able to get their medicine in one form or another, we know that this has been a very difficult time for many people, and we thank them for their understanding and patience through this time.”

New Zealand is one of the highest users in the world of metoprolol succinate, used to treat angina and hypertension, which means sourcing other stock internationally is difficult. PHARMAC recognizes this and have put additional safeguards in place to help prevent future issues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK